These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23188075)

  • 1. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study.
    Smith JP; Field D; Bingaman SI; Evans R; Mauger DT
    J Clin Gastroenterol; 2013 Apr; 47(4):339-45. PubMed ID: 23188075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.
    Smith JP; Bingaman SI; Ruggiero F; Mauger DT; Mukherjee A; McGovern CO; Zagon IS
    Dig Dis Sci; 2011 Jul; 56(7):2088-97. PubMed ID: 21380937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose naltrexone therapy improves active Crohn's disease.
    Smith JP; Stock H; Bingaman S; Mauger D; Rogosnitzky M; Zagon IS
    Am J Gastroenterol; 2007 Apr; 102(4):820-8. PubMed ID: 17222320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
    Patten DK; Schultz BG; Berlau DJ
    Pharmacotherapy; 2018 Mar; 38(3):382-389. PubMed ID: 29377216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats.
    Tawfik DI; Osman AS; Tolba HM; Khattab A; Abdel-Salam LO; Kamel MM
    Neuropeptides; 2016 Oct; 59():39-45. PubMed ID: 27392602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
    Szabó D; Kökönyei G; Arató A; Dezsőfi A; Molnár K; Müller KE; Lakatos PL; Papp M; Lovász BD; Golovics PA; Cseh A; Veres G
    J Crohns Colitis; 2014 Aug; 8(8):747-55. PubMed ID: 24434181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
    Yanai H; Levine A; Hirsch A; Boneh RS; Kopylov U; Eran HB; Cohen NA; Ron Y; Goren I; Leibovitzh H; Wardi J; Zittan E; Ziv-Baran T; Abramas L; Fliss-Isakov N; Raykhel B; Gik TP; Dotan I; Maharshak N
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):49-59. PubMed ID: 34739863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.
    Bolton M; Hodkinson A; Boda S; Mould A; Panagioti M; Rhodes S; Riste L; van Marwijk H
    BMC Med; 2019 Jan; 17(1):10. PubMed ID: 30642329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate for maintenance of remission in Crohn's disease.
    Patel V; Wang Y; MacDonald JK; McDonald JW; Chande N
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006884. PubMed ID: 25157445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis for the treatment of Crohn's disease.
    Kafil TS; Nguyen TM; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient.
    Shannon A; Alkhouri N; Mayacy S; Kaplan B; Mahajan L
    Inflamm Bowel Dis; 2010 Sep; 16(9):1457. PubMed ID: 20014017
    [No Abstract]   [Full Text] [Related]  

  • 18. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study.
    Mayer L; Pandak WM; Melmed GY; Hanauer SB; Johnson K; Payne D; Faleck H; Hariri RJ; Fischkoff SA
    Inflamm Bowel Dis; 2013; 19(4):754-60. PubMed ID: 23429460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.